Patient Outreach May Improve Awareness of Diabetic Peripheral Neuropathy

Six Month Grace Period to Regain Compliance with Nasdaq Continued Listing Rule

Company is Addressing Diabetes-Related Nerve Disease

NeuroMetrix to Exhibit at the Midwest Podiatry Conference WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 10, 2012-- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes reported today that it will exhibit at the

NeuroMetrix, Inc. Announces Date for 2012 First Quarter Financial Results Conference Call WALTHAM, Mass., Apr 17, 2012 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO) today said it plans to issue its 2012 first quarter financial results before the opening of the market on April 24, 2012.

NeuroMetrix Files 510(k) for SENSUS(TM) Pain Therapy Device WALTHAM, Mass., Apr 18, 2012 (BUSINESS WIRE) --NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes reported today that it has filed a premarket

Investigating the Impact of Intensive Diabetes Management on Diabetic Peripheral Neuropathy

Operational and Strategic Progress in Diabetes Business

Business Focus on Diabetes-Related Nerve Damage

Malvern (U.K.) Diabetic Foot Conference on May 9-12, 2012